Development of hopo-101 as an MCM (medical countermeasure) decorporation agent for the treatment of individuals with known or suspected internal contamination with radionuclides (the ?MCM indication?)…

Active Definitive Contract Awarded Last action

Contract number
75A50124C00062
Awardee
Awarding agency
Obligated
$14,209,253

Award facts

Contract value 6% obligated
  • $14,209,253.00 Current, with exercised options
  • $231,149,540.00 Potential, with all options
Completion date 42% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Berkeley, CA 94704, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00004 $4,839,729
Other Administrative Action P00003 · The purpose of this modification is to: $0
Other Administrative Action P00002 · The purpose of this modification is to: 1. Extend the base period, clin 0001, at no additional cost through 28 february 2026. $0
Other Administrative Action P00001 · The purpose of this modification is to: $0
Original award $9,369,524

About this award

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a definitive cost-plus-fixed-fee contract to Hopo Therapeutics, Inc. for development of HOPO-101 as a medical countermeasure decorporation agent for treatment of internal contamination with radionuclides and toxic heavy metals, with a ceiling value of $231,149,540 and an award date of September 30, 2024.

This modification provides an additional $4,839,729 in funding for CLIN 0001 and extends the period of performance for that line item to December 31, 2026. The statement of work has been updated to Revision V20MAR2026. Place of performance is Berkeley, California.

The contract originated from BARDA's open solicitation for advanced research and development of medical countermeasures against CBRN threats, pandemic influenza, and emerging infectious diseases. The underlying solicitation contemplates multiple awards of various values and contract types across twelve areas of interest, with a final proposal submission deadline of September 25, 2028. Work must be performed in the United States, with preference for U.S.-based manufacturing and technologies adaptable to emerging threats. All submissions must comply with Good Manufacturing Practice standards, export control regulations, intellectual property disclosure requirements, and GLP, GMP, and GCP guidelines as applicable.

The ultimate contract completion date is September 30, 2029.

Description

As the agency reported it.

Development of hopo-101 as an MCM (medical countermeasure) decorporation agent for the treatment of individuals with known or suspected internal contamination with radionuclides (the ?MCM indication?) and/or toxic heavy metals of interest for commerc

Quick answers

Who was awarded contract 75A50124C00062?

75A50124C00062 was awarded to Hopo Therapeutics, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2024.

How much is contract 75A50124C00062 worth?

The government has obligated $14,209,253 on 75A50124C00062. Its potential value, with all options, is $231,149,540.

Was contract 75A50124C00062 competed?

The extent of competition for 75A50124C00062 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login